세계의 급성 빈발 발작 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 지역별 전망, 예측(2023-2030년)

Acute Repetitive Seizures Market - Global Acute Repetitive Seizures Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -

US $ 4,995 ￦ 6,922,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,772,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,689,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 급성 빈발 발작 시장 규모는 2023-2030년 30%의 CAGR로 확대하며, 2030년까지 135억 달러에 달할 것으로 예측되고 있습니다.

급성 빈발 발작 시장을 촉진하는 주요 동향 중 하나는 발작을 적절히 제어할 수 있는 치료 공백이 존재한다는 것입니다. 현재 많은 환자들이 효과적인 치료법을 이용할 수 없기 때문에 혁신적인 치료법에 대한 수요가 부각되고 있으며, 이는 제약회사들이 연구개발(R&D)에 대한 투자를 촉진하고 있습니다. 이는 환자 치료를 개선하는 것뿐만 아니라 큰 시장 기회를 의미합니다.

세계 헬스케어 산업의 급속한 성장도 급성 빈발 발작 시장을 자극하는 중요한 추세입니다. 의료 인프라가 성장함에 따라 의료에 대한 접근성이 증가함에 따라 효과적인 발작 관리에 대한 수요도 증가하고 있습니다. 이 시장은 세계 헬스케어 산업의 확장으로 인한 혜택을 누릴 수 있을 것으로 보입니다.

항경련제(AED)는 입증된 효과, 다양한 선택지, 제형 개선 및 부작용 감소를 위한 지속적인 연구개발 노력으로 인해 급성 빈발 발작 시장에서 크게 성장하고 있으며, AED는 발작 관리에 적합한 선택이 되고 있습니다.

경구 투여는 편의성, 환자의 순응도, 경구용 AED의 광범위한 가용성으로 인해 급성 빈발 발작 시장에서 중요성이 커지고 있습니다. 이 비침습적 방법은 장기적인 발작 관리를 단순화하여 시장 성장에 기여하고 있습니다.

병원은 급성 빈발 발작 시장의 주요 유통 채널로 부상하고 있으며, 급성 빈발 발작 관리의 주요 거점이 되고 있습니다. 반면, 재택 치료는 환자 중심 치료, 휴대용 의료기기, 원격의료의 발전과 함께 효율적이고 편리한 재택 치료로 성장하고 있습니다.

세계의 급성 빈발 발작 시장에 대해 조사했으며, 시장의 개요와 약제 유형별, 투여 경로별, 유통 채널별, 최종 용도별, 지역별 동향 및 시장에 참여하는 기업의 경쟁 동향 등을 제공하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아의 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 급성 빈발 발작 시장 전망, 2018-2030년

• 세계의 급성 빈발 발작 시장 전망, 약제 유형별, 금액(10억 달러), 2018-2030년
• 세계의 급성 빈발 발작 시장 전망, 투여 경로별, 금액(10억 달러), 2018-2030년
• 세계의 급성 빈발 발작 시장 전망, 유통 채널별, 금액(10억 달러), 2018-2030년
• 세계의 급성 빈발 발작 시장 전망, 최종 용도별, 금액(10억 달러), 2018-2030년
• 세계의 급성 빈발 발작 시장 전망, 지역별, 금액(10억 달러), 2018-2030년

제4장 북미의 급성 빈발 발작 시장 전망, 2018-2030년

제5장 유럽의 급성 빈발 발작 시장 전망, 2018-2030년

제6장 아시아태평양의 급성 빈발 발작 시장 전망, 2018-2030년

제7장 라틴아메리카의 급성 빈발 발작 시장 전망, 2018-2030년

제8장 중동 및 아프리카의 급성 빈발 발작 시장 전망, 2018-2030년

제9장 경쟁 구도

• 유통 채널과 용도 히트맵
• 제조업체와 용도 히트맵
• 기업의 시장 점유율 분석, 2022년
• 경쟁력 대시보드
• 기업 개요
  • Pfizer
  • Novartis
  • GlaxoSmithKline
  • Eisai Co. Ltd.
  • UCB Pharmaceuticals
  • Lundbeck
  • UCB
  • Acquestive Therapeutics
  • Marinus Pharmaceuticals
  • Takeda Pharmaceuticals
  • SK Biopharmaceuticals
  • Supernus Pharmaceuticals
  • Neurelis Inc.
  • Sage Therapeutics
  • NeuroPace

제10장 부록

• 조사 방법
• 리포트 전제조건
• 두자어와 약어

KSA

영문 목차

영문목차

Global Acute Repetitive Seizures Market Projected to Reach $13.5 Billion by 2030: Rapid Growth and Key Trends Shape the Industry.

The global acute repetitive seizures market is on a trajectory of remarkable growth, with projections indicating a market size of $13.5 billion by the end of 2030, driven by a robust CAGR of 30% between 2023 and 2030. Fairfield Market Research's latest report provides a comprehensive overview of this burgeoning market, highlighting key trends, growth determinants, and the competitive landscape.

Key Trends Driving Growth in the Acute Repetitive Seizures Market

Presence of a Treatment Gap and R&D Initiatives: One of the primary trends propelling the acute repetitive seizures market is the presence of a treatment gap in achieving adequate seizure control. Many patients currently lack access to effective therapies, highlighting the demand for innovative treatments and prompting pharmaceutical companies to invest in research and development (R&D). This not only enhances patient care but also represents a significant market opportunity.

Rapidly Expanding Global Healthcare Industry: The global healthcare industry's rapid expansion is another major trend fueling the acute repetitive seizures market. As healthcare infrastructure grows, so does access to care and the demand for effective seizure management. The market is set to profit from the worldwide healthcare industry's expansion.

Dominance of Antiepileptic Drugs (AEDs): Antiepileptic drugs (AEDs) are experiencing significant growth in the acute repetitive seizures market due to their well-established efficacy, diverse options, and continuous R&D efforts leading to improved formulations and reduced side effects. AEDs have become the preferred choice for seizure management.

Growing Importance of the Oral Route: The oral route of administration is gaining prominence in the acute repetitive seizures market due to its convenience, patient compliance, and the wide availability of AEDs in oral forms. This non-invasive method simplifies long-term seizure management, contributing to its growth.

Hospitals and Home Care Settings: Hospitals are emerging as a key distribution channel in the acute repetitive seizures market, serving as primary centers for acute seizure management. In contrast, home care settings are growing due to the trend toward patient-centric care, portable medical devices, and telemedicine, making home care efficient and convenient.

Regional Insights

North America Leads the Way: North America has captured the largest market share in the acute repetitive seizures market. This dominance is attributed to its advanced healthcare infrastructure, high disease prevalence, strong R&D investments, favorable regulations, and a robust pharmaceutical industry. North America plays a dominant role in seizure management and treatment.

Asia Pacific Shows Exceptional Growth: The Asia Pacific region is poised to witness the highest CAGR in the acute repetitive seizures market. Factors such as a large patient population, increasing healthcare infrastructure, rising awareness, and expanding access to care are driving remarkable growth in this rapidly evolving market.

Competitive Landscape

The global acute repetitive seizures market is characterized by consolidation, with a select group of major players dominating the industry. These key players, including Pfizer, Novartis, GlaxoSmithKline, Eisai Co., Ltd, UCB Pharmaceuticals, Lundbeck, UCB, Aquestive Therapeutics, Marinus Pharmaceuticals, Takeda Pharmaceuticals, SK Biopharmaceuticals, Supernus Pharmaceuticals, Neurelis, Inc., Sage Therapeutics, NeuroPace, Inc and others, are actively introducing new products and expanding their distribution channels to bolster their international presence.

Table of Contents

1. Executive Summary

• 1.1. Global Acute Repetitive Seizures Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2022
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. Covid-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Acute Repetitive Seizures Market Outlook, 2018 - 2030

• 3.1. Global Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
  • 3.1.1. Key Highlights
    • 3.1.1.1. Antiepileptic Drugs (AEDs)
    • 3.1.1.2. Benzodiazepines
    • 3.1.1.3. Barbiturates
    • 3.1.1.4. Others
• 3.2. Global Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
  • 3.2.1. Key Highlights
    • 3.2.1.1. Oral
    • 3.2.1.2. Intravenous
    • 3.2.1.3. Intranasal
• 3.3. Global Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
  • 3.3.1. Key Highlights
    • 3.3.1.1. Hospitals
    • 3.3.1.2. Specialty Clinics
    • 3.3.1.3. Retail Pharmacies
    • 3.3.1.4. Online Pharmacies
• 3.4. Global Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 3.4.1. Key Highlights Snacks
    • 3.4.1.1. Hospitals
    • 3.4.1.2. Clinics
    • 3.4.1.3. Home Care Settings
• 3.5. Global Acute Repetitive Seizures Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
  • 3.5.1. Key Highlights
    • 3.5.1.1. North America
    • 3.5.1.2. Europe
    • 3.5.1.3. Asia Pacific
    • 3.5.1.4. Latin America
    • 3.5.1.5. Middle East & Africa

4. North America Acute Repetitive Seizures Market Outlook, 2018 - 2030

• 4.1. North America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
  • 4.1.1. Key Highlights
    • 4.1.1.1. Antiepileptic Drugs (AEDs)
    • 4.1.1.2. Benzodiazepines
    • 4.1.1.3. Barbiturates
    • 4.1.1.4. Others
• 4.2. North America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
  • 4.2.1. Key Highlights
    • 4.2.1.1. Oral
    • 4.2.1.2. Intravenous
    • 4.2.1.3. Intranasal
• 4.3. North America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
  • 4.3.1. Key Highlights
    • 4.3.1.1. Hospitals
    • 4.3.1.2. Specialty Clinics
    • 4.3.1.3. Retail Pharmacies
    • 4.3.1.4. Online Pharmacies
• 4.4. North America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 4.4.1. Key Highlights
    • 4.4.1.1. Hospitals
    • 4.4.1.2. Clinics
    • 4.4.1.3. Home Care Settings
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis
• 4.5. North America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 4.5.1. Key Highlights
    • 4.5.1.1. U.S. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 4.5.1.2. U.S. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 4.5.1.3. U.S. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.5.1.4. U.S. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 4.5.1.5. Canada Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 4.5.1.6. Canada Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 4.5.1.7. Canada Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.5.1.8. Canada Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
  • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Acute Repetitive Seizures Market Outlook, 2018 - 2030

• 5.1. Europe Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
  • 5.1.1. Key Highlights
    • 5.1.1.1. Antiepileptic Drugs (AEDs)
    • 5.1.1.2. Benzodiazepines
    • 5.1.1.3. Barbiturates
    • 5.1.1.4. Others
• 5.2. Europe Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
  • 5.2.1. Key Highlights
    • 5.2.1.1. Oral
    • 5.2.1.2. Intravenous
    • 5.2.1.3. Intranasal
• 5.3. Europe Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
  • 5.3.1. Key Highlights
    • 5.3.1.1. Hospitals
    • 5.3.1.2. Specialty Clinics
    • 5.3.1.3. Retail Pharmacies
    • 5.3.1.4. Online Pharmacies
• 5.4. Europe Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospitals
    • 5.4.1.2. Clinics
    • 5.4.1.3. Home Care Settings
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis
• 5.5. Europe Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 5.5.1. Key Highlights
    • 5.5.1.1. Germany Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.5.1.2. Germany Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.5.1.3. Germany Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.5.1.4. Germany Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.1.5. U.K. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.5.1.6. U.K. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.5.1.7. U.K. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.5.1.8. U.K. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.1.9. France Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.5.1.10. France Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.5.1.11. France Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.5.1.12. France Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.1.13. Italy Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.5.1.14. Italy Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.5.1.15. Italy Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.5.1.16. Italy Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.1.17. Spain Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.5.1.18. Spain Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.5.1.19. Spain Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.5.1.20. Spain Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.1.21. Rest of Europe Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.5.1.22. Rest of Europe Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.5.1.23. Rest of Europe Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.5.1.24. Rest of Europe Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
  • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acute Repetitive Seizures Market Outlook, 2018 - 2030

• 6.1. Asia Pacific Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
  • 6.1.1. Key Highlights
    • 6.1.1.1. Antiepileptic Drugs (AEDs)
    • 6.1.1.2. Benzodiazepines
    • 6.1.1.3. Barbiturates
    • 6.1.1.4. Others
• 6.2. Asia Pacific Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
  • 6.2.1. Key Highlights
    • 6.2.1.1. Oral
    • 6.2.1.2. Intravenous
    • 6.2.1.3. Intranasal
• 6.3. Asia Pacific Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
  • 6.3.1. Key Highlights
    • 6.3.1.1. Hospitals
    • 6.3.1.2. Specialty Clinics
    • 6.3.1.3. Retail Pharmacies
    • 6.3.1.4. Online Pharmacies
• 6.4. Asia Pacific Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospitals
    • 6.4.1.2. Clinics
    • 6.4.1.3. Home Care Settings
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis
• 6.5. Asia Pacific Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 6.5.1. Key Highlights
    • 6.5.1.1. China Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.5.1.2. China Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.5.1.3. China Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.5.1.4. China Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.1.5. Japan Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.5.1.6. Japan Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.5.1.7. Japan Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.5.1.8. Japan Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.1.9. India Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.5.1.10. India Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.5.1.11. India Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.5.1.12. India Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.1.13. Southeast Asia Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.5.1.14. Southeast Asia Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.5.1.15. Southeast Asia Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.5.1.16. Southeast Asia Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.1.17. Rest of Asia Pacific Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.5.1.18. Rest of Asia Pacific Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.5.1.19. Rest of Asia Pacific Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.5.1.20. Rest of Asia Pacific Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acute Repetitive Seizures Market Outlook, 2018 - 2030

• 7.1. Latin America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
  • 7.1.1. Key Highlights
    • 7.1.1.1. Antiepileptic Drugs (AEDs)
    • 7.1.1.2. Benzodiazepines
    • 7.1.1.3. Barbiturates
    • 7.1.1.4. Others
• 7.2. Latin America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
  • 7.2.1. Key Highlights
    • 7.2.1.1. Oral
    • 7.2.1.2. Intravenous
    • 7.2.1.3. Intranasal
• 7.3. Latin America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
  • 7.3.1. Key Highlights
    • 7.3.1.1. Hospitals
    • 7.3.1.2. Specialty Clinics
    • 7.3.1.3. Retail Pharmacies
    • 7.3.1.4. Online Pharmacies
• 7.4. Latin America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospitals
    • 7.4.1.2. Clinics
    • 7.4.1.3. Home Care Settings
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis
• 7.5. Latin America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 7.5.1. Key Highlights
    • 7.5.1.1. Brazil Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 7.5.1.2. Brazil Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.5.1.3. Brazil Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.5.1.4. Brazil Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 7.5.1.5. Mexico Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 7.5.1.6. Mexico Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.5.1.7. Mexico Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.5.1.8. Mexico Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 7.5.1.9. Rest of Latin America Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 7.5.1.10. Rest of Latin America Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.5.1.11. Rest of Latin America Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.5.1.12. Rest of Latin America Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
  • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acute Repetitive Seizures Market Outlook, 2018 - 2030

• 8.1. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
  • 8.1.1. Key Highlights
    • 8.1.1.1. Antiepileptic Drugs (AEDs)
    • 8.1.1.2. Benzodiazepines
    • 8.1.1.3. Barbiturates
    • 8.1.1.4. Others
• 8.2. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
  • 8.2.1. Key Highlights
    • 8.2.1.1. Oral
    • 8.2.1.2. Intravenous
    • 8.2.1.3. Intranasal
• 8.3. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
  • 8.3.1. Key Highlights
    • 8.3.1.1. Hospitals
    • 8.3.1.2. Specialty Clinics
    • 8.3.1.3. Retail Pharmacies
    • 8.3.1.4. Online Pharmacies
• 8.4. Middle East & Africa Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
  • 8.4.1. Key Highlights
    • 8.4.1.1. Hospitals
    • 8.4.1.2. Clinics
    • 8.4.1.3. Home Care Settings
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis
• 8.5. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
  • 8.5.1. Key Highlights
    • 8.5.1.1. GCC Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 8.5.1.2. GCC Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.5.1.3. GCC Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.5.1.4. GCC Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 8.5.1.5. South Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 8.5.1.6. South Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.5.1.7. South Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.5.1.8. South Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 8.5.1.9. Rest of Middle East & Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
    • 8.5.1.10. Rest of Middle East & Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.5.1.11. Rest of Middle East & Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.5.1.12. Rest of Middle East & Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
  • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Distribution Channel vs Application Heatmap
• 9.2. Manufacturer vs Application Heatmap
• 9.3. Company Market Share Analysis, 2022
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Pfizer
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Product Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Novartis
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Product Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. GlaxoSmithKline
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Product Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. Eisai Co. Ltd.
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Product Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. UCB Pharmaceuticals
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Product Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. Lundbeck
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Product Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. UCB
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Product Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development
  • 9.5.8. Acquestive Therapeutics
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Product Portfolio
    • 9.5.8.3. Business Strategies and Development
  • 9.5.9. Marinus Pharmaceuticals
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Product Portfolio
    • 9.5.9.3. Financial Overview
    • 9.5.9.4. Business Strategies and Development
  • 9.5.10. Takeda Pharmaceuticals
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Product Portfolio
    • 9.5.10.3. Financial Overview
    • 9.5.10.4. Business Strategies and Development
  • 9.5.11. SK Biopharmaceuticals
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Product Portfolio
    • 9.5.11.3. Financial Overview
    • 9.5.11.4. Business Strategies and Development
  • 9.5.12. Supernus Pharmaceuticals
    • 9.5.12.1. Company Overview
    • 9.5.12.2. Product Portfolio
    • 9.5.12.3. Financial Overview
    • 9.5.12.4. Business Strategies and Development
  • 9.5.13. Neurelis Inc.
    • 9.5.13.1. Company Overview
    • 9.5.13.2. Product Portfolio
    • 9.5.13.3. Financial Overview
    • 9.5.13.4. Business Strategies and Development
  • 9.5.14. Sage Therapeutics
    • 9.5.14.1. Company Overview
    • 9.5.14.2. Product Portfolio
    • 9.5.14.3. Financial Overview
    • 9.5.14.4. Business Strategies and Development
  • 9.5.15. NeuroPace
    • 9.5.15.1. Company Overview
    • 9.5.15.2. Product Portfolio
    • 9.5.15.3. Financial Overview
    • 9.5.15.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료